1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Alcon, Inc.

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Fribourg, Switzerland.
David J. Endicott

rue Louis-d'Affry 6


Alcon Announces its Largest-Ever Scientific Program at the 41st Congress of the ESCRS, Showcasing New Data and Innovation to Support Ophthalmic Surgical Teams | ALC Stock News
Sep 06, 2023 21:30pm

Alcon, the global leader in eye care dedicated to helping people see brilliantly, will present a robust lineup of scientific

Source:Stock Titan
Christina Ackermann Joins Verona Pharma as Non-Executive Director
Aug 31, 2023 06:00am

LONDON and RALEIGH, N.C., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (NASDAQ: VRNA ) ("Verona Pharma"), announces effective September 1, 2023, Ms. Christina Ackermann will join the board as a Non-Executive Director. Ms. Ackermann brings over 25 years of legal and management experience across the pharmaceutical, device and consumer products industries. Most recently, she served as Executive Vice President, General Counsel and Global President Ophthalmic Pharmaceuticals at Bausch + Lomb Corporation where she was responsible for strategic planning and worldwide commercialization of pharmaceutical prescription assets across the portfolio as well as global legal affairs. Previously, Ms. Ackermann was part of the Novartis group of companies for 14 years where she served in multiple leadership roles of increasing responsibility including Global Head, Legal and General Counsel of Alcon and Sandoz. Earlier in her career, Ms. Ackermann held Associate General Counsel roles at both Bristol-Myers Squibb and DuPont Pharmaceuticals. "We are pleased to welcome Christina to the Board," said Dr.

JP Morgan upgrades Alcon to overweight in wake of earnings beat
Aug 17, 2023 15:18pm

JP Morgan’s European desk has upgraded Alcon (ALC) to overweight, commenting that concerns about growth in the implantables market is likely to be “short-lived.” Read more here.

Source:Seeking Alpha
Asia looks ''very positive'' to us in terms of growth, Alcon CEO says
Aug 17, 2023 07:02am

David Endicott, CEO of Alcon, discusses its second-quarter earnings.

JPMorgan upgrades Alcon to ''overweight'' with a price target of $89.30
Aug 17, 2023 05:00am
JPMorgan upgrades Alcon to ''overweight'' with a price target of CHF78.60
Aug 17, 2023 05:00am
Alcon Inc. (ALC) Q2 2023 Earnings Call Transcript
Aug 16, 2023 15:29pm

Alcon Inc. (NYSE:NYSE:ALC) Q2 2023 Earnings Conference Call August 16, 2023 8:00 AM ETCompany ParticipantsDaniel Cravens - Vice President, Investor RelationsDavid Endicott - Chief Executive…

Source:Seeking Alpha
Alcon Q2 2023 Earnings Preview
Aug 15, 2023 21:35pm

Alcon (ALC) is scheduled to announce Q2 earnings results on Wednesday, August 16th, after market close.The consensus EPS Estimate is $0.65 (+3.2% Y/Y) and the consensus Revenue Estimate…

Source:Seeking Alpha
Alcon Non-GAAP EPS of $0.69 beats by $0.04, revenue of $2.4B beats by $20M
Aug 15, 2023 20:49pm

Alcon press release (ALC): Q2 Non-GAAP EPS of $0.69 beats by $0.04.Revenue of $2.4B (+9.1% Y/Y) beats by $20M.2023 Outlook: Net sales $9.3 to $9.5 billion; Change vs

Source:Seeking Alpha
Alcon Inc. Swiss: Alcon Reports Second Quarter 2023 Results
Aug 15, 2023 20:36pm

Second quarter 2023 sales of $2.4 billion, up 9%, or 12% constant currency(1) (cc) Second quarter 2023 diluted EPS of $0.34, up 13%, or up 34% cc; core diluted EPS(2) of $0.69 up 10%, or 19% cc Ba…

Source:Finanz Nachrichten